()
 

Overview

Simcere Pharmaceutical Group (NYSE: SCR - News) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti- stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 35 pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious ...

Contact Information

No 699-18 Xuan Wu Avenue
Xuan Wu District
Nanjing, 210042

tel: 86 25 8556 6666
fax: 86 25 8547 1729
http://www.simcere.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NYSE
Industry: Drug Manufacturers - Other
Market Cap: $911.8M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.